TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06961214: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 961 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,344,488

Rescue Site Savings

+$5,515,848

Unlock Full NCT06961214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06961214 Rescue Dossier →